Question · Q3 2016
David Stubbs from Raymond James, on behalf of Ren Benjamin, requested details on the potential Phase III trial for GALE-401, including enrollment, timing, and endpoints, and also asked for guidance on the future cash burn rate.
Answer
President & CEO Mark Schwartz explained that the GALE-401 trial will likely target essential thrombocythemia patients who have failed first-line therapy, utilizing an accelerated 505(b)(2) regulatory pathway, and he anticipated trial initiation in Q2 2017. VP Finance John Burns addressed the financials, stating that while Q4 2016 cash burn guidance is $7-$9 million, the burn rate is expected to decrease in 2017 as costs from discontinued operations subside, with more specific guidance to come.